Heart Attack Diagnostics Market to Hit USD 21.38 Bn by 2032 | SNS Insider

Rising cardiovascular cases, AI-driven diagnostics, and advanced biomarkers fuel 7.64% CAGR growth in the Heart Attack Diagnostics Market.

AUSTIN, TX, UNITED STATES, February 25, 2025 /EINPresswire.com/ -- According to SNS Insider, the Heart Attack Diagnostics Market was valued at USD 11.01 billion in 2023 and is projected to reach USD 21.38 billion by 2032, expanding at a CAGR of 7.64% during the forecast period (2024-2032).

The Heart Attack Diagnostics Market is growing remarkably owing to the increasing incidence of cardiovascular disease, enhanced awareness of early diagnosis, and the evolution of diagnostic technology. Growing demand for high-sensitivity troponin testing, electrocardiogram (ECG), and imaging technology is being influenced by better healthcare facilities as well as government support. Moreover, the increasing use of point-of-care testing and artificial intelligence-based diagnostic products is improving the rate of early detection, further driving market growth.

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/5776

Segmentation Analysis

By Test, the Blood Test segment dominated the heart attack diagnostics market and accounted for 55.26% market share in 2023.

Blood Test provides high accuracy, quick results, and reliability in identifying cardiac biomarkers like troponin and CK-MB. All diagnostic techniques notwithstanding, troponin tests are the gold standard for the detection of myocardial infarction since they provide early and accurate identification of heart injury. The growing use of point-of-care blood tests in emergency rooms and outpatient locations has also entrenched the segment's hold. Moreover, technological developments with high-sensitivity troponin assays have improved heart attack early diagnosis, lowering mortality and enhancing patient outcomes. The growing rate of cardiovascular disease burden worldwide, combined with increasing awareness of regular cardiac screening, has also driven demand for blood-based diagnostic tests through 2023.

By End-use, the ambulatory surgical centers (ASCS) segment dominated the heart attack diagnostics market with a 53.29% market share in 2023.

The ambulatory surgical centers dominated because more people preferred budget-friendly and effective healthcare services away from conventional hospital settings. ASCs provide quicker diagnostic services, shorter wait times for patients, and lower expenditures, making them a popular choice for both patients and healthcare professionals. The increasing use of point-of-care diagnostic equipment, such as portable ECG machines and high-sensitivity troponin tests, has further boosted the dominance of the segment. Moreover, technological advancements in minimally invasive procedures and better reimbursement policies have further enhanced the position of ASCs in cardiac diagnostics. The trend toward outpatient treatment and early intervention further boosted the dominance of this segment. Increasing investments in telemedicine integration and ambulatory care infrastructure are set to further boost this trend.

Regional Insights
North America dominated the heart attack diagnostics market with around 38% market share in 2023

The region's dominance is attributed to its advanced healthcare infrastructure, high spending on healthcare, and the prevalent nature of sophisticated diagnostic technologies. North America is favorably positioned because of good reimbursement policies, enhanced use of high-sensitivity cardiac biomarker testing, and availability of major industry players such as Abbott, Siemens Healthineers, and Beckman Coulter. Furthermore, the increasing incidence of cardiovascular diseases, facilitated by sedentary lifestyles, obesity, and high cholesterol levels, further accelerates market growth, led by the U.S. in terms of diagnostic innovation.

Asia Pacific is the fastest-growing region with the highest CAGR of 8.75% throughout the forecast period, due to expanding healthcare investments, high urbanization rates, and a mounting burden of cardiovascular disease. Regions such as China, India, and Japan are witnessing a rise in demand for early and precise heart attack diagnosis, fueled by changes in lifestyle and population aging. Government campaigns that raise awareness of cardiac health, increase access to point-of-care diagnostic technologies, and grow the use of low-cost diagnostic technologies are fueling market growth.

Speak with Our Expert Analyst Today to Gain Deeper Insights @ https://www.snsinsider.com/request-analyst/5776

Key Players in the Market:
• Abbott Laboratories (ARCHITECT STAT High Sensitivity Troponin-I Assay, i-STAT System)
• Beckman Coulter (Access hsTnI Assay, DxI 800 Immunoassay System)
• Bio-Rad Laboratories, Inc. (Cardiac Marker Control, Liquichek Cardiac Markers Plus Control)
• Siemens Healthineers (ADVIA Centaur TnI-Ultra Assay, Atellica IM 1300 Analyzer)
• GE Healthcare (MAC 2000 Resting ECG System, CardioSoft Diagnostic System)
• Hitachi Medical Systems (HI VISION Avius Ultrasound System, Noblus Portable Ultrasound)
• Schiller AG (CARDIOVIT AT-102 G2 ECG Device, MAGLIFE RT-1 Patient Monitor)
• Koninklijke Philips N.V. (PageWriter TC70 Cardiograph, IntelliVue MX700 Patient Monitor)
• F. Hoffmann-La Roche Ltd. (Elecsys Troponin T-high sensitive Assay, Cobas h 232 POC System)
• Bayer AG (CONTOUR Blood Glucose Monitoring System, Multistix 10 SG Reagent Strips)
• bioMérieux, Inc. (VIDAS Troponin I Ultra Assay, VIDAS NT-proBNP Assay)
• Danaher Corporation (Triage Cardiac Panel, Dimension EXL with LM Integrated Chemistry System)
• Life Sign LLC (Status DS Troponin I Test, Status First Aid Rapid Test)
• Toshiba Corporation (Aquilion ONE CT Scanner, Aplio i-series Ultrasound)
• FUJIFILM Holdings (FDR Go PLUS Portable X-ray System, Arietta 850 Ultrasound)
• Midmark Corporation (IQecg Digital ECG, IQvitals Zone Vital Signs Monitor)
• Hill-Rom Services (Welch Allyn) (CP 150 Resting ECG, Connex Spot Monitor)
• Canon Medical Systems Corporation (Aquilion Prime SP CT System, Aplio i800 Ultrasound)
• Bionet Co., Ltd. (CardioTouch 3000 ECG, BM3 Patient Monitor)
• Edwards Lifesciences Corporation (FloTrac Hemodynamic Monitoring System, ClearSight System)

Buy Full Research Report on Heart Attack Diagnostics Market 2024-2032 @ https://www.snsinsider.com/checkout/5776

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram